Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation

Bone Marrow Transplantation

Volumn 41, Issue 5, 2008, Pages 483-493

  Loren, A W ^a   Porter, D L ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ALLOGENEIC STEM CELL TRANSPLANTATION; CANCER CELL; DONOR; DONOR LYMPHOCYTE INFUSION; ERADICATION THERAPY; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; PRIORITY JOURNAL; REVIEW;

ADULT; GRAFT VS HOST DISEASE; GRAFT VS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LEUKEMIA, MYELOID, ACUTE; LEUKOCYTE TRANSFUSION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 40749121702     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705898     Document Type: Review

References (100)

1. Barnes D, Corp M, Loutit J, Neal F. Treatment of murine leukaemia with X rays and homologous bone marrow. Preliminary communication. Br Med J 1956; 2: 626-630.
2. Barnes D, Loutit J. Treatment of murine leukaemia with X-rays and homologous bone marrow. Br J Haematol 1957; 3: 241-252.
3. Mathe G, Amiel J, Schwarzenberg L, Cattan A, Schneider M. Adoptive immunotherapy of acute leukemia: Experimental and clinical results. Cancer Res 1965; 25: 1525-1531.
4. Weiden P, Flournoy N, Donnall Thomas E, Prentice R, Fefer A, Buckner C et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 1979; 300 1068-1073.
5. Horowitz M, Gale R, Sondel P, Goldman J, Kersey J, Kolb H et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555-562.
6. Gale R, Horowitz M, Ash R, Champlin R, Goldman J, Rimm A et al. Identical-twin bone marrow transplants for leukemia. Ann Int Med 1994; 120: 646-652.
7. Kolb H, Mittermuller J, Clemm C, Holler E, Ledderose G, Brehm G et al Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 76: 2462-2465.
8. Porter D, Roth M, McGarigle C, Ferrara J, Antin J. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med 1994; 330: 100-106.
9. Collins R, Shpilberg O, Drobyski W, Porter D, Giralt S, Champlin R et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997; 15: 433-444.
10. Kolb H, Schattenberg A, Goldman J, Hertenstein B, Jacobsen N, Arcese W et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995; 86: 2041-2050.
11. Drobyski W, Keever C, Roth M, Koethe S, Hanson G, McFadden P et al. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: Efficacy and toxicity of a defined T-cell dose. Blood 1993; 82: 2310-2318.
12. Porter D, Collins R, Shpilberg O, Drobyski W, Connors J, Sproles A et al. Long-term follow-up of patients who achieved complete remission after donor leukocyte infusions. Biol Blood Marrow Transplant 1999; 5: 253-261.
13. Dazzi F, Szydlo RM, Cross NC, Craddock C, Kaeda J, Kanfer E et al. Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 2000; 96: 2712-2716.
14. Porter D, Roth M, Lee S, McGarigle C, Ferrara J, Antin J. Adoptive immunotherapy with donor mononuclear cell infusions to treat relapse of acute leukemia or myelodysplasia after allogeneic bone marrow transplantation. Bone Marrow Transplant 1996; 18: 975-980.
15. Slavin S, Naparstek E, Nagler A, Ackerstein A, Samuel S, Kapelushnik J et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood 1996; 87: 2195-2204.
16. Szer J, Grigg A, Phillipos G, Sheridan W. Donor leucocyte infusions after chemotherapy for patients relapsing with acute leukaemia following allogeneic BMT. Bone Marrow Transplant 1993; 11: 109-111.
17. Shiobara S, Nakao S, Ueda M, Yamazaki H, Takahashi S, Asano S et al Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: Lower incidence of acute graft-versus-host disease and improved outcome. Bone Marrow Transplant 2000; 26: 769-774.
18. Choi SJ, Lee JH, Kim S, Seol M, Lee YS, Lee JS et al. Treatment of relapsed acute myeloid leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: A high incidence of isolated extramedullary relapse. Leukemia 2004; 18: 1789-1797.
19. Collins Jr RH, Goldstein S, Giralt S, Levine J, Porter D, Drobyski W et al. Donor leukocyte infusions in acute lymphocytic leukemia. Bone Marrow Transplant 2000; 26: 511-516.
20. Levine J, Braun T, Penza S, Beatty P, Cornetta K, Martino R et al. Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem cell transplantation. J Clin Oncol 2002; 20: 405-412.
21. Cunningham I. Extramedullary sites of leukemia relapse after transplant. Leuk Lymphoma 2007; 47: 1754-1767.
22. Singhal S, Powles R, Kulkarni S, Treleaven J, Saso R, Mehta J. Long-term follow-up of relapsed acute leukemia treated with immunotherapy after allogeneic transplantation: The inseparability of graft-versus-host disease and graft-versus-leukemia, and the problem of extramedullary relapse. Leuk Lymphoma 1999; 32: 505-512.
23. Berthou C, Leglise MC, Herry A, Balcon D, Hardy E, Lessard M et al Extramedullary relapse after favorable molecular response to donor leukocyte infusions for recurring acute leukemia. Leukemia 1998; 12: 1676-1681.
24. Chong G, Byrnes G, Szer J, Grigg A. Extramedullary relapse after Allogeneic bone marrow transplantalion for haematological malignancy. Bone Marrow Transplant 1011; 26: 1011-1015.
25. Slavin S, Morecki S, Weiss L, Or R. Donor lymphocyte infusion: The use of alloreactive and tumor-reactive lymphocytes for immunotherapy of malignant and nonmalignant diseases in conjunction with allogeneic stem cell transplantation. Hematother Stem Cell Res 2002; 11: 265-276.
26. Choi SJ, Lee JH, Kim S, Lee YS, Seol M, Ryu SG et al. Treatment of relapsed acute lymphoblastic leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: A prospective study. Bone Marrow Transplant 2005; 36: 163-169.
27. Cardoso A, Schultze J, Boussiotis VA, Freeman GJ, Seamon MJ, Laszlo S et al. Pre-B acute lymphoblastic leukemia cells may induce T cell anergy to alloantigen. Blood 1996; 88: 41-48.
28. Galandrini R, Albi N, Zarcone D, Grossi CE, Velardi A. Adhesion molecule-mediated signals regulate major histo-compatibility complex-unrestricted and CD3/T cell receptor-triggered cytotoxicity. Eur J Immunol 1992; 22: 2047-2053.
29. Han P, Story C, McDonald T, Mrozik K, Snell L. Immune escape mechanisms of childhood ALL and a potential countering role for DC-like leukemia cells. Cytotherapy 2002; 4: 165-175.
30. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. [See comment]. Science 2002; 295: 2097-2100.
31. Loren A, Luger S, Stadtmauer E, Tsai D, Schuster S, Nasta S et al. Intensive graft-versus-host disease prophylaxis is required after unrelated donor non-myeloablative stem cell transplantation. Bone Marrow Transplant 2005; 35: 921-926.
32. Morris EC, Rebello P, Thomson KJ, Peggs KS, Kyriakou C, Goldstone AH et al. Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: Relevance for early adoptive immunotherapy and infectious complications. Blood 2003; 102: 404-406.
33. Spitzer T, McAfee S, Sackstein R, Colby C, Toh H, Multani P et al. Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies. Biol Blood Marrow Transplant 2000; 6: 309-320.
34. Peggs KS, Thomson K, Hart DP, Geary J, Morris EC, Yong K et al. Dose-escalated donor lymphocyte infusions following reduced intensity transplantatidn: Toxicity, chimerism, and disease responses. [See comment]. Blood 2004; 103: 1548-1556.
35. Tauro S, Craddock C, Peggs K, Begum G, Mahendra P, Cook G et al. Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. J Clin Oncol 2005; 23: 9387-9393.
36. Schmid C, Schleuning M, Ledderose G, Tischer J, Kolb HJ. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myolodysplastic syndrome. J Clin Oncol 2005; 23: 5675-5687.
37. de Lima M, Bonamino M, Vasconcelos Z, Colares M, Diamond H, Zalcberg I et al. Prophylactic donor lymphocyte infusions After moderately ablative chemotherapy and stem cell transplantation for hematological malignancies: High remission rate among poor prognosis patients at the expense of graft-versus-host disease. Bone Marrow Transplant 2001; 27: 71-78.
38. Antin JH, Childs R, Filipovich AH, Giralt S, Mackinnon S, Spitzer T et al. Establishment of complete and, mixed donor chimerism after allogeneic lymphohematopoietic transplantation: Recommendations from a workshop at the 2001 Tandem meetings of the International bone marrow transplant registry and the American society of blood and marrow transplantation. Biol Blood Marrow Transplant 2001; 7: 473-485.
39. Antin J. Stem cell transplantation-harnessing of graft-vs-malignancy. Curr Opin Hematol 2003, 10: 440-444.
40. Marks DI, Lush R, Cavenagh J, Milligan DW, Schey S, Parker A et al The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation. Blood 2002; 100: 3108-3114.
41. Bethge WA, Hegenbart U, Stuart MJ, Storer BE, Maris MB, Flowers ME et al. Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning. [See comment]. Blood 2004; 103: 790-795.
42. Dey BR, McAfee S, Colby C, Sackstein R, Saidman S, Tarbell N et al Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation. Biol Blood Marrow Transplant 2003; 9: 320-329.
43. Loren A, Porter D. Donor leukocyte infusions after unrelated donor hematopoietic stem cell transplantation. Curr Opin Oncol 2006; 18: 107-114.
44. Flowers M, Leisenring W, Beach K, Riddell S, Radich J, Higano C et al Granulocyte colony-stimulating factor given to donors before apheresis does not prevent aplasia in patients treated with donor leukocyte infusion for recurrent chronic myeloid leukemia after bone marrow transplantation. Biol Blood Marrow Transplant 2000; 6 321-326.
45. Giralt S, Hester J, Huh Y, Hirsch-Ginsberg C, Rondon G, Seong D et al CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood 1995; 86: 4337-4343.
46. Mehta J, Powles R, Treleaven J, Horton C, Meller S, Pinkerton C et al Outcome of acute leukemia relapsing after bone marrow transplantation: Utility of second transplants and adoptive immunotherapy. Bone Marrow Transplant 1997; 19: 709-719.
47. van Rhee R, Savage D, Blackwell J, Orchard K, Dazzi F, Lin F et al Adoptive immunotherapy for relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: Equal efficacy of lymphocytes from sibling and matched unrelated donors. Bone Marrow Transplant 1998; 21: 1055-1061.
48. Porter D, Coilins R, Hardy C, Kernan N, Drobyski W, Giralt S et al Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions. Blood 2000; 95: 1214-1221.
49. Porter D, Antin J. Adoptive immunotherapy in bone marrow transplantation. In: Burakoff S, Deeg H, Ferrara J (eds). Graft-versus-Host-Disease. Marcel Dekker: New York, 1997, pp 733-754.
50. Mackinnon S, Papadopoulos E, Carabasi M, Reich L, Collins N, Boulad F et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: Separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995; 86: 1261-1268.
51. Korbling M, Giralt S, Khouri I, Mirza N, Donato M, Anderlini P et al Donor lymphocyte apheresis for adoptive immunotherapy compared with blood stem cell apheresis. J Clin Apher 2001; 16: 82-87.
52. Alyea E, Soiffer R, Canning C, Neuberg D, Schlossman R, Pickett C et al. Toxicity and efficacy of defined doses of CD4+ donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood 1998; 91: 3671-3680.
53. Soiffer R, Alyea E, Hochberg E, Wu C, Canning C, Parikh B et al. Randomized trial of CD8+ T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion. Biol Blood Marrow Transplant 2002; 8: 625.
54. SCTC Group. Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: An individual patient data meta-analysis of nine randomized trials. J Clin Oncol 2005; 23: 5074-5087.
55. Schmitz N, Barrett J. Optimizing engraftment - source and dose of stem cells. Semin Hematol 2002; 39: 3-14.
56. Bensinger WI, Deeg HJ. Blood or marrow? Lancet 2000; 355: 1199-1200.
57. Morris ES, MacDonald KP, Hill GR. Stem cell mobilization with G-CSF analogs: A rational approach to separate GVHD and GVL? Blood 2006; 107: 3430-3435.
58. MacDonald KP, Rowe V, Filippich C, Johnson D, Morris ES, Clouston AD et al. Chronic graft-versus-host disease after granulocyte colony-stimulating factor-mobilized allogeneic stem cell transplantation: The role of donor T-cell dose and differentiation. Biol Blood Marrow Transplant 2004; 10: 373-385.
59. Shiobara S, Nakao S, Ueda M, Yamazaki H, Takahashi S, Asano S et al Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: Indications and dose escalation. Ther Apher 2001; 5: 40-45.
60. Porter D, Antin J. Graft-versus-leukemia effect of allogeneic bone marrow transplantation and donor mononuclear cell infusions. In: Winter J (ed). Blood Stem Cell Transplantation. Kluwer Academic Publishers: Norwell, MA, 1997, pp 57-86.
61. Akpek G, Boitnott JK, Lee LA, Hallick JP, Torbenson M, Jacobsohn DA et al. Hepatitic variant of graft-versus-host disease after donor lymphocyte infusion. Blood 2002; 100: 3903-3907.
62. Marks DI, Lush R, Cavenagh J, Milligan DW, Schey S, Parker A et al The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation. Blood 2002; 100: 3108-3114.
63. Alessandrino EP, Bernasconi P, Caldera D, Colombo A, Malcovati L, Martinelli G et al. Chemotherapy and donor peripheral blood progenitor cells for acute leukemia in early relapse after allogeneic bone marrow transplantation. Bone Marrow Transplant 1999; 23 607-612.
64. Siegert W, Beyer J, Kingreen D, Blasczyk R, Baurmann H, Schwella N et al. Treatment of relapse after allogeneic bone marrow transplantation with unmanipulated G-CSF-mobilized peripheral blood stem cell preparation. Bone Marrow Transplant 1998; 22: 579-583.
65. Keil F, Haas OA, Fritsch G, Kalhs P, Lechner K, Mannhalter C et al Donor leukocyte infusion for leukemic relapse after allogeneic marrow transplantation: Lack of residual donor hematopoiesis predicts aplasia. Blood 1997; 89: 3113-3117.
66. Liebowitz D, Lee K, CH J. Costimulatory approaches to adoptive immunotherapy. Curr Opin Oncol 1998; 10: 533-541.
67. Laport GG, Levine BL, Stadtmauer EA, Schuster SJ, Luger SM, Grupp S et al. Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34 + -selected hematopoietic cell transplantation. Blood 2003; 102: 2004-2013.
68. Rapoport A, Stadtmauer E, Aqui N, Badros A, Cotte J, Chrisley L et al Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nat Med 2005; 11: 1230-1237.
69. Porter DL, Levine BL, Bunin N, Stadtmauer EA, Luger SM, Goldstein S et al. A phase I trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 co-stimulation. Blood 2006; 107: 1325-1331.
70. Cardoso AA, Seamon MJ, Afonso HM, Ghia P, Boussiotis VA, Freeman GJ et al. Ex vivo generation of human anti-pre-B leukemia-specific autologous cytolytic T cells. Blood 1997; 90: 549-561.
71. Kolb HJ, Schmid C, Barrett AJ, Schendel DJ. Graft-versus-leukemia reactions in allogeneic chimeras. Blood 2004, 103: 767-776.
72. Miklos DB, Kim HT, Zorn E, Hochberg EP, Guo L, Mattes-Ritz A et al Antibody response to DBY minor histocompatibility antigen is indnced after allogeneic stem cell transplantation and in healthy female donors. Blood 2004; 103: 353-359.
73. Zorn E, Miklos DB, Noyd BH, Mattes-Ritz A, Guo L, Soiffer RJ et al Minor histocompatibility antigen DBY elicits a coordinated B and T cell response after allogeneic stem cell transplantation. J Exp Med 2004; 199: 1133-1142.
74. Bocchia M, Korontsvit T, Xu Q, Mackinnon S, Yang SY, Sette A et al Specific human cellular immunity to bcr-abl oncogene-derived peptides. Blood 1996; 87: 3587-3592.
75. Clark RE, Dodi IA, Hill SC, Lill JR, Aubert G, Macintyre AR et al. Direct evidence that leukemic cell present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein. Blood 2001; 98: 2887-2893.
76. Voogt PJ, Goulmy E, Veenhof WF, Hamilton M, Fibbe WE, Van Rood JJ et al. Cellularly defined minor histocompatibility antigens are differentially expressed on human hematopoietic progenitor cells. J Exp Med 1988; 168: 2337-2347.
77. Mutis T, Verdijk R, Schrama E, Esendam B, Brand A, Goulmy E. Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens. Blood 1999; 93: 2336-2341.
78. Marijt WA, Heemskerk MH, Kloosterboer FM, Goulmy E, Kester MG, van der Hoorn MA et al. Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia. Proc Natl Acad Sci USA 2003; 100: 2742-2747.
79. Randolph SS, Gooley TA, Warren EH, Appelbaum FR, Riddell SR, Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants. Blood 2004; 103: 347-352.
80. Molldrem J, Dermime S, Parker K, Jiang YZ, Mavroudis D, Hensel N et al. Targeted T-cell therapy for human leukemia: Cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. Blood 1996; 88: 2450-2457.
81. Molldrem JJ, Lee PP, Wang C, Felio K, Kantarjian HM, Champlin RE et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 2000; 6 1018-1023.
82. Heslop HE, Stevenson FK, Molldrem JJ. Immunotherapy of hematologic malignancy. Hematology Am Soc Hematol Educ Program 2003, 331-349.
83. Rosenfeld C, Cheever MA, Gaiger A. WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: Therapeutic potential of WT1 targeted therapies. Leukemia 2003; 17: 1301-1312.
84. Tamaki H, Ogawa H, Ohyashiki K, Ohyashiki JH, Iwama H, Inoue K et al The Wilms' tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes. Leukemia 1999; 13: 393-399.
85. Atanackovic D, Arfsten J, Cao Y, Gnjatic S, Schnieders F, Bartels K et al. Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation. Blood 1103; 109: 1103-1112.
86. Greiner J, Schmitt M, Li L, Giannopoulos K, Bosch K, Schmitt A et al Expression of tumor-associated antigens in acute myeloid leukemia: implications for specific immunotherapeutic approaches. Blood 2006; 108: 4109-4117.
87. Falkenburg JH, Wafelman AR, Joosten P, Smit WM, van Bergen CA, Bongaerts R et al. Complete remission of, accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes. Blood 1999; 94: 1201-1208.
88. Montagna D, Maccario R, Montini E, Tonelli R, Lisini D, Pagani S et al. Generation and ex vivo expansion of cytotoxic T lymphocytes directed toward different types of leukemia or myelodysplastic cells using both HLA-matched and partially matched donors. Exp Hematol 2003; 31: 1031-1038.
89. Dudley ME, Wunderlich JR, Shelton TE, Even J, Rosenberg SA. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother (1997) 2003; 26: 332-342.
90. Figlin RA, Pierce WC, Kaboo R, Tso CL, Moldawer N, Gitlitz B et al Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8(+) selected tumor infiltrating lymphocytes from primary tumor. J Urol 1997; 158: 740-745.
91. Servida P, Rossini S, Traversari C, Ferrari G, Bonini C, Nobili N et al. Gene transfer into peripheral blood lymphocytes for in vivo immunomodulation of donor anti-tumor immunity in a patient affected by EBV-induced lymphoma. Blood 1993; 82: 214a.
92. Bonini C, Ferrari G, Verzeletti S, Servida P, Zappone E, Ruggieri L et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 1997; 276: 1719-1724.
93. Johnson BD, Becker EE, LaBelle JL, Truitt RL. Role of immunoregulatery donor T cells in suppression of graftversus-host disease following donor leukocyte infusion therapy. J Immunol 1999; 163: 6479-6487.
94. Johnson BD, Konkol MC, Truitt RL. CD25+ immunoregulatory T-cells of donor origin suppress alloreactivity after BMT. Biol Blood Marrow Transplant 2002; 8: 525-535.
95. Trenado A, Sudres M, Tang Q, Maury S, Charlotte F, Gregoire S et al. Ex vivo-expanded CD4 + CD25 + immunoregulatory T cells prevent graft-versus-host-discase by inhibiting activation/differentiation of pathogenic T cells. J Immunol 2006; 176: 1266-1273.
96. Fowler DH, Odom J, Steinberg SM, Chow CK, Foley J, Kogan Y et al. Phase I clinical trial of costimulated, IL-4 polarized donor CD4 + T cells as augmentation of allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2006; 12: 1150-1160.
97. Xia G, Truitt RL, Johnson BD. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras. Biol Blood Marrow Transplant 2006; 12: 397-407.
98. Mapara MY, Kim YM, Wang SP, Bronson R, Sachs DH, Sykes M. Donor lymphocyte infusions mediate superior graft-versus-leukemia effects in mixed compared to fully allogeneic chimeras: A critical role for host antigen-presenting cells. Blood 2002; 100: 1903-1909.
99. Matte CC, Liu J, Cormier J, Anderson BE, Athanasiadis I, Jain D et al Donor APCs are required for maximal GVHD but not for GVL. Nat Med 2004; 10: 987-992.
100. Shlomchik W, Couzens M, Tang C, McNiff J, Robert M, Liu J et al. Prevention of graft-versus-host disease by inactivation of tost antigen-presenting cells. Science 1999; 285: 412-415.